A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (EAE116)
Latest Information Update: 26 May 2022
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma; Renal impairment
- Focus Therapeutic Use
- 26 May 2022 Status changed to recruiting, according to Eudra source.
- 28 Mar 2022 Planned initiation date changed from 1 Dec 2021 to 1 Apr 2022.
- 09 Dec 2021 New trial record